Daily Stock Analysis, ADVM, Adverum Biotechnologies Inc, priceseries

Adverum Biotechnologies Inc. Daily Stock Analysis
Stock Information
Open
10.87
Close
10.56
High
11.25
Low
10.44
Previous Close
10.99
Daily Price Gain
-0.43
YTD High
16.38
YTD High Date
Jul 16, 2019
YTD Low
2.90
YTD Low Date
Jan 30, 2019
YTD Price Change
7.15
YTD Gain
209.68%
52 Week High
16.38
52 Week High Date
Jul 16, 2019
52 Week Low
2.62
52 Week Low Date
Nov 2, 2018
52 Week Price Change
4.61
52 Week Gain
77.48%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Sep 8. 2017
2.80
Sep 25. 2017
3.24
11 Trading Days
15.74%
Link
LONG
Dec 18. 2017
3.20
Jan 9. 2018
3.87
14 Trading Days
21.05%
Link
LONG
Jan 16. 2018
4.35
Feb 6. 2018
6.59
15 Trading Days
51.50%
Link
LONG
Aug 17. 2018
5.20
Sep 6. 2018
6.59
13 Trading Days
26.80%
Link
LONG
Jan 31. 2019
3.18
Mar 8. 2019
4.42
25 Trading Days
38.91%
Link
LONG
Mar 11. 2019
4.70
Mar 25. 2019
5.45
10 Trading Days
16.05%
Link
LONG
Apr 18. 2019
5.98
May 8. 2019
6.54
13 Trading Days
9.40%
Link
LONG
May 16. 2019
8.13
Jun 14. 2019
10.85
20 Trading Days
33.45%
Link
LONG
Jul 3. 2019
11.62
Jul 18. 2019
14.31
10 Trading Days
23.17%
Link
Company Information
Stock Symbol
ADVM
Exchange
NasdaqGM
Company URL
http://www.adverumbio.com
Company Phone
650-272-6269
CEO
Amber Salzman
Headquarters
California
Business Address
1035 O'BRIEN DRIVE, MENLO PARK, CA 94025
Sector
-
Industry Category
-
Industry Group
-
CIK
0001501756
About

Adverum Biotechnologies, Inc. is a clinical-stage biotechnology company that engages in the development of novel gene therapies to treat patients with sight-threatening ophthalmic diseases. It focuses on treatment of wet age-related macular degeneration, alpha-1 antitrypsin deficiency, hereditary angioedema, friedreich's ataxia, severe allergy, color vision deficiency, and juvenile x-linked retinoschisis. The company was founded by Mark S. Blumenkranz, Thomas W. Chalberg, Jr. and Steven Daniel Schwartz on July 17, 2006 and is headquartered in Menlo Park, CA.

Description

Avalanche Biotechnologies, Inc., a gene therapy company, engages in discovering and developing novel medicines that offer therapeutic benefit to patients suffering from chronic or debilitating disease. It primary focuses on developing AVA-101, which is in a Phase IIa trial for the treatment of wet age-related macular degeneration (AMD). The company is also developing AVA-201, a product candidate for the prevention of wet AMD; AVA-311 that is in preclinical studies for the treatment of juvenile X-linked retinoschisis, a rare genetic disease of the retina with no approved therapy; and AVA-322 and AVA-323 for the treatment of color vision deficiency. Avalanche Biotechnologies, Inc. has a collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize gene therapy products. The company was founded in 2006 and is headquartered in Menlo Park, California.